News and Trends 26 May 2023
Rocket Pharmaceuticals receives FDA designation for pyruvate kinase deficiency gene therapy
Rocket Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to RP-L301, the company’s investigational lentiviral-based gene therapy for…
